SEC Contract Filing

Filing Date: 2021-11-22

Document Content:
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>ex10-1.htm
<DESCRIPTION>SETTLEMENT AGREEMENT
<TEXT>
<HTML>
<HEAD>
 <TITLE></TITLE>
</HEAD>

<BODY style="font: 10pt Times New Roman, Times, Serif; font-family: Times New Roman, Times, serif;">
 <!-- Edge Version : NotProvided -->
 <div align="LEFT" style="margin-bottom: 0pt; margin-top: 3pt;">
 <div style="border-bottom: Black 1pt solid; border-top: Black 2pt solid; padding-bottom: 0; width: 100%; font-size: 1pt;">&nbsp;</div>
 </div>
 <p style="margin: 0;"><A HREF="admp-10q_063021.htm">Adamis Pharmaceuticals, Corporation 10-Q</A></p>
 <p style="margin: 0; text-align: right; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>

<P STYLE="text-align: right; margin: 0"><B>Exhibit 10.1</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 3.55pt 0 0; text-align: left">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 3.55pt 0 12pt; text-align: left">[***]&nbsp;&nbsp;Certain information
in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is both not material and is
the type that the Registrant treats as private or confidential.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 3.55pt 0 ; text-align: center">SETTLEMENT AGREEMENT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.05pt 0 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 9pt; text-align: justify; text-indent: 35.8pt">This Settlement
Agreement <B>(&ldquo;Agreement&rdquo;) </B>is entered into among Nephron Pharmaceuticals Corporation, Nephron S.C., Inc., and Nephron
Sterile Compounding Center, LLC <B>(&ldquo;Nephron&rdquo; </B>or <B>&ldquo;Plaintiff&rsquo;),</B> and U.S. Compounding, Inc. <B>(&ldquo;U.S.
Compounding&rdquo;),</B> Adamis Pharmaceuticals Corporation <B>(&ldquo;Adamis&rdquo;),</B> Jennifer Shelly Hulsey <B>(&ldquo;Hulsey&rdquo;),</B>
and Jessica Ingrid Lane <B>(&ldquo;Lane&rdquo;)</B> (together hereinafter <B>&ldquo;Defendants&rdquo;). </B>Nephron and Defendants are
collectively hereinafter referred to as the &ldquo;Parties&rdquo;.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 105.9pt 12pt; text-align: center">RECITALS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 9.2pt; text-align: justify; text-indent: 36.1pt"><B>WHEREAS,
</B>Nephron Pharmaceuticals Corporation is a corporation organized and existing under and by virtue of the laws of the State of Florida
with its principal place of business located at 4121 SW 34<SUP>th</SUP> Street, Orlando, Florida, 32811;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 9.4pt; text-align: justify; text-indent: 36.15pt"><B>WHEREAS,
</B>Nephron S.C., Inc. is a corporation organized and existing under and by virtue of the laws of the State of South Carolina with its
principal place of business located at 4500 12<SUP>th</SUP> Street Extension, West Columbia, South Carolina, 29172;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 9.4pt; text-align: justify; text-indent: 36.15pt"><B>WHEREAS,</B> Nephron Sterile Compounding Center,
LLC a corporation with its principal place of business located at 4500 12<SUP>th</SUP> Street Extension, West Columbia, South Carolina,
29172;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 9.7pt; text-align: justify; text-indent: 36.1pt"><B>WHEREAS,
</B>U.S. Compounding, Inc. is a corporation organized and existing under and by virtue of the laws of the State of Arkansas with its principal
place of business located at 1270 Don&rsquo;s Lane, Conway, Arkansas, 72032;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 9.4pt; text-align: justify; text-indent: 36.15pt"><B>WHEREAS,</B>
Adamis Pharmaceuticals Corporation is a California corporation that is the parent corporation of U.S. Compounding with its principal place
of business located at 11682 El Camino Real, Suite 300, San Diego, California, 92130;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 9.4pt; text-align: justify; text-indent: 36.15pt"><B>WHEREAS,</B> Shelly Hulsey is a natural person domiciled
in the State of Kansas;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 9.4pt; text-align: justify; text-indent: 36.15pt"><B>WHEREAS,</B> Jessica Lane is a natural person domiciled
in the State of New Jersey;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 9.4pt; text-align: justify; text-indent: 36.15pt"><B>WHEREAS,</B>
on September 21, 2018, Nephron commenced litigation in the United States District Court for the Middle District of Florida (the <B>&ldquo;Florida
Court&rdquo;),</B> styled <I>Nephron Pharmaceuticals Corporation, Nephron S.C., Inc., and Nephron Sterile Compounding Center, LLC v.
Jennifer Shelly Hulsey and U.S. Compounding, Inc. d/b/a U.S. Compounding Pharmacy, originally assigned case number 6:18-cv-1573-ORL-31-KRS
and ultimately assigned case number 6:18-cv-01573-GAP-LRH (the <B>&ldquo;Florida Lawsuit&rdquo;),</B> alleging, without limitation, that
Hulsey and</I> U.S. Compounding collectively misappropriated certain trade secrets from Nephron;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 9.4pt; text-align: justify; text-indent: 36.15pt"><B>WHEREAS,</B>
on March <B>1 , 2019,</B> Nephron filed a second amended complaint in the Florida Lawsuit, adding Adamis as a defendant, and alleging
various claims against Hulsey, U.S. Compounding, and Adamis including, without limitation, that they collectively misappropriated certain
trade secrets from Nephron;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 103.65pt 0 ; text-align: center">Page <B>1</B> of <B>12</B></P>

<!-- Field: Page; Sequence: 1 -->
 <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE=